Collegium Pharmaceutical (COLL) vs Pharming Group N.V. (PHAR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Pharming Group N.V. (PHAR) has outperformed Collegium Pharmaceutical (COLL) over the past year, losing 29.0% versus a loss of 45.2%. Over five years, PHAR leads with a +39.0% price change compared with +37.7% for COLL. Pharming Group N.V. is the larger company by market cap ($816.8 million vs $768.2 million), about 1.1 times the size.
On valuation, Collegium Pharmaceutical trades at a lower forward P/E (3.5x vs 64.1x for Pharming Group N.V.). Collegium Pharmaceutical converts more of its revenue into profit, with a net margin of 8.1% versus 0.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COLL | PHAR |
|---|---|---|
| Share price | $24.72 | $11.54 |
| Market cap | $768.18M | $816.78M |
| 1-day change | -1.94% | -5.10% |
| YTD return | -46.61% | -34.69% |
| 1-year return | -45.24% | -29.03% |
| 5-year return | +37.72% | +39.04% |
| P/E ratio (TTM) | 22.68 | 36.06 |
| Forward P/E | 3.49 | 64.11 |
| EPS (TTM) | $1.09 | $0.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $780.57M | $376.13M |
| Revenue growth (YoY) | +23.62% | +26.56% |
| Net income (latest FY) | $62.87M | $2.85M |
| Gross margin | 59.35% | 87.90% |
| Operating margin | 23.01% | 6.87% |
| Net margin | 8.05% | 0.76% |
| 52-week high | $50.79 | $21.34 |
| 52-week low | $21.43 | $9.11 |
| Distance from 52-week high | -51.33% | -45.92% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +77.99% | +209.36% |
| Average volume | 754.45K | 21.33K |
| Shares outstanding | 31.08M | 70.78M |
| Employees | 423 | 407 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PHAR has outperformed COLL by 16.2 percentage points over the past year.
- Pharming Group N.V. trades at a higher earnings multiple (36.1x vs 22.7x trailing P/E).
- Collegium Pharmaceutical is more profitable, keeping 8.1 cents of every revenue dollar as net income versus 0.8 cents for Pharming Group N.V..
About Collegium Pharmaceutical
COLL stock →Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 423 employees
About Pharming Group N.V.
PHAR stock →Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kd inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 407 employees
COLL vs PHAR FAQ
Which is bigger, Collegium Pharmaceutical or Pharming Group N.V.?
Pharming Group N.V. (PHAR) is larger, with a market capitalization of $816.78M compared with $768.18M for Collegium Pharmaceutical (COLL).
Which stock has performed better over the past year, COLL or PHAR?
PHAR returned -29.03% over the past 12 months, compared with -45.24% for COLL (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, COLL or PHAR?
COLL has the lower trailing P/E at 22.7, versus 36.1 for PHAR. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Collegium Pharmaceutical and Pharming Group N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.